Ottobock stock: Deutsche Bank cuts price target to EUR 56
Published on 11/21/2026 at 11:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view shifts after quarterly update
- Deutsche Bank maintained its Buy rating on Ottobock.
- Reimbursement hurdles and longer approval procedures shaped the bank's revised assessment.
- Ottobock's investor calendar points to the German Equity Forum on November 23.
Deutsche Bank Research lowered its price target for Ottobock to 56 euros from 85 euros on Tuesday, November 17, while maintaining its Buy rating. Marketscreener reported that analyst Falko Friedrichs linked the revised view to unexpected reimbursement difficulties and longer approval procedures.
Reimbursement risks weigh on outlook
The bank said the latest figures had dampened investor sentiment toward the prosthetics manufacturer, but it retained its positive investment stance. The assessment followed Ottobock's third-quarter update, which the company published on November 12.
Ottobock's investor page describes the group as a medical technology provider focused on prosthetics, neuro-orthotics and exoskeletons. Its calendar lists the German Equity Forum in Frankfurt for November 23, giving investors a near-term opportunity to hear further company presentations.
Ottobock stock traded at 37.83 euros on Lang & Schwarz at 11:57 CET on Saturday, November 21.
Ottobock company facts
- Company: Ottobock SE & Co. KGaA
- ISIN: DE000BCK2223
- Latest quote: 37.83 euros on Lang & Schwarz, November 21, 2026, 11:57 CET
- Analyst view: Deutsche Bank Buy rating
German equities remain the broader market context for Ottobock stock. Current market reports provide the wider regional backdrop.
